Genmab — September 2013
-
jeg har gravet rundt i de offenliggjorte data, men kan ikke rigtig finde noget. Hverken fra GSK eller fra Roche
-
fandt lige Roches data - median age ranged from 72 to 74, with up to 45% of patients ≥75 years, depending on the cohort - See more at: median age ranged from 72 to 74, with up to 45% of patients ≥75 years, depending on the cohort, http://www.onclive.com/publications/oncology-live/2013/july-2013/GA101-Shows-Gains-in-Pivotal-CLL-Trial
-
dejligt at komme tilbage til 207+
-
det ligner noget kraftig
modstand her i 208 -
og så alligevel ikke - sikke en gevinst, der har været i den BTD! 1-2% som FF sagde...
-
-
det slog mig lige, at de beregninger jeg har lavet på Novods tal (med peaksales på 1,6 mia i cll first line) kun forholder sig til US markedet. Hvis vi tager world wide er hans peaksales lig med en markdsandel under 5%!!!
-
jep - arzerra+dara+cash og intet andet
-
Novod lægger så cash til sin valuation, hvor FF tilsyneladende trækker den fra...
-
congrats stoft. Velkommen tilbage. den er klokket ind i 216
-
Novod har 9 kurspoint på "partner income excisting deals" hvilket nok henviser til duobody, inclacumab mv.
puha
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind